IceCure Medical Ltd (NASDAQ:ICCM – Get Free Report) saw a large drop in short interest in the month of September. As of September 15th, there was short interest totalling 393,100 shares, a drop of 9.2% from the August 31st total of 432,900 shares. Based on an average trading volume of 542,000 shares, the days-to-cover ratio is currently 0.7 days. Approximately 1.7% of the shares of the company are sold short.
Analyst Ratings Changes
Separately, HC Wainwright reiterated a “buy” rating and issued a $2.50 price objective on shares of IceCure Medical in a research report on Thursday, September 12th.
Read Our Latest Stock Analysis on ICCM
IceCure Medical Stock Performance
IceCure Medical (NASDAQ:ICCM – Get Free Report) last issued its earnings results on Tuesday, August 20th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.01. IceCure Medical had a negative return on equity of 111.27% and a negative net margin of 410.22%. The business had revenue of $1.01 million during the quarter, compared to analysts’ expectations of $0.90 million. During the same period in the prior year, the firm posted ($0.09) EPS. On average, analysts forecast that IceCure Medical will post -0.27 EPS for the current year.
Hedge Funds Weigh In On IceCure Medical
An institutional investor recently bought a new position in IceCure Medical stock. Renaissance Technologies LLC bought a new position in IceCure Medical Ltd (NASDAQ:ICCM – Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 66,400 shares of the company’s stock, valued at approximately $49,000. Renaissance Technologies LLC owned approximately 0.15% of IceCure Medical at the end of the most recent quarter. 0.62% of the stock is currently owned by institutional investors and hedge funds.
IceCure Medical Company Profile
IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.
See Also
- Five stocks we like better than IceCure Medical
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Simon Property REIT: A Safe Bet for Growth and Steady Dividends
- What Are Growth Stocks and Investing in Them
- CarMax’s Impressive Rally: What Investors Should Watch Next
- Compound Interest and Why It Matters When Investing
- MarketBeat Week in Review – 9/23 – 9/27
Receive News & Ratings for IceCure Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IceCure Medical and related companies with MarketBeat.com's FREE daily email newsletter.